Cytokeratin-19 and Mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7183-7193

  Reinholz, Monica M ^a,e   Kitzmann, Kathleen A ^a   Tenner, Kathleen ^a   Hillman, David ^a   Dueck, Amylou C ^b   Hobday, Timothy J ^a   Northfelt, Donald W ^b   Moreno Aspitia, Alvaro ^c   Roy, Vivek ^c   LaPlant, Betsy ^a   Allred, Jake B ^a   Stella, Philip J ^d   Lingle, Wilma L ^a   Perez, Edith A ^c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d Saint Joseph Mercy Health System   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CAPECITABINE; CD45 ANTIGEN; CETUXIMAB; CYTOKERATIN 19; ERLOTINIB; GEMCITABINE; IRINOTECAN; MAMMAGLOBIN; MESSENGER RNA; PACLITAXEL POLIGLUMEX; SORAFENIB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CYTOKERATIN 19 GENE; DISEASE ASSOCIATION; FEASIBILITY STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LABORATORY; MAJOR CLINICAL STUDY; MAMMAGLOBIN GENE; MASTECTOMY; METASTASIS; METASTATIC BREAST CANCER; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KERATIN-19; MAMMAGLOBIN A; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 81255165025     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0981     Document Type: Article

References (50)

1. Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert Rev Anticancer Ther 2010;10:171-7.
2. Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009;35:463-74.
3. Ring A, Smith IE, Dowsett M. Circulating tumour cells in breast cancer. Lancet Oncol 2004;5:79-88. (Pubitemid 38145890)
4. Hayes DF, Smerage JB. Circulating tumor cells. Prog Mol Biol Transl Sci 2010;95:95-112.
5. Ignatiadis M, Georgoulias V, Mavroudis D. Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 2008;44:2726-36.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
7. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
8. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
9. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8. (Pubitemid 46340368)
10. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9. (Pubitemid 44799711)
11. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, FritscheHA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471-9. (Pubitemid 46424284)
12. Riethdorf S, Pantel K. Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci 2010;1210:66-77.
13. Demel U, Tilz GP, Foeldes-Papp Z, Gutierrez B, Albert WH, Bocher O. Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. J Exp Clin Cancer Res 2004;23:465-8. (Pubitemid 39490631)
14. Hauch S, ZimmermannS, Lankiewicz S,Zieglschmid V,Bocher O, Albert WH. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res 2007;27:1337-41. (Pubitemid 46807280)
15. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res 2005;11:3722-32. (Pubitemid 40685589)
16. Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 2002;8:1871-7. (Pubitemid 34633748)
17. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 2009; 117:525-34.
18. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007;25:5194-202. (Pubitemid 350232250)
19. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008;14:2593-600.
20. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62. (Pubitemid 46622314)
21. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM). Guidance for Industry. Bioanalytical Method Validation 2001.
22. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
23. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-93.
24. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91. (Pubitemid 43080010)
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Reseach and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
27. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009;115:581-90.
28. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 2010;10:666.
29. Shen C, Hu L, Xia L, Li Y. The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem 2009;42:194-200.
30. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prové A, et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010;102:276-84.
31. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:885-92. (Pubitemid 44291136)
32. Núñez-Villar MJ, Martínez-Arribas F, Pollán M, Lucas AR, Sánchez J, Tejerina A, et al. Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 2003;5:R65-70.
33. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with low-grade, steroid receptor- positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004;22:691-8. (Pubitemid 41095073)
34. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005;43:617-27. (Pubitemid 41460612)
35. Giribaldi G, Procida S, Ulliers D, Mannu F, Volpatto R, Mandili G, et al. Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. J Mol Diagn 2006; 8:105-12. (Pubitemid 43257441)
36. Kahn HJ, Presta A, Yang LY, Blondal J, Trudeau M, Lickley L, et al. Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat 2004;86:237-47. (Pubitemid 39070966)
37. Taubert H, Blümke K, Bilkenroth U, Meye A, Kutz A, Bartel F, et al. Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases. Gynecol Oncol 2004;92:256-61. (Pubitemid 38147401)
38. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009;113:501-7.
39. Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, White E, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg 2010;136:1274-9.
40. Lin YC, Chen SC, Hsueh S, Lo YF, Chow-Wu YH, Liaw IC, et al. Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients. Cancer Sci 2003;94:99-102. (Pubitemid 36575866)
41. Bitisik O, Saip P, Saglam S, Derin D, Dalay N. Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2010; 9:97-106.
42. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9. (Pubitemid 46224178)
43. Wülfing P, Borchard J, Buerger H, Heidl S, Zänker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006;12: 1715-20.
44. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003;88:1091-4. (Pubitemid 36560781)
45. Benoy IH, Elst H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, et al. Detection of circulating tumour cells in blood by quantitative realtime RT-PCR: effect of pre-analytical time. Clin Chem Lab Med 2006;44:1082-7. (Pubitemid 44370926)
46. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010;21:1851-7.
47. Hekimian K, Stein E-L, Pachmann K, Pachman K. Detection of tumor stem cells among circulating epithelial tumor cells. 7th International Symposium on Minimal Residual Cancer 2009;76: abstr 012.
48. You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol 2008;1:2.
49. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009;118:455-68.
50. Reinholz MM, Mandrekar SJ, Foster N, Meyers JP, Kitzmann KA, Jett JR, et al. Circulating tumor cell cytokeratin-19 gene expression as a prognostic factor in lung cancer: Analysis based on North Central Cancer Treatment Group (NCCTG) clinical trials (N0423/426). J Thorac Oncol 2011;6:S1076-S7.